Compare · AORT vs MDLN
AORT vs MDLN
Side-by-side comparison of Artivion Inc. (AORT) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AORT and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $50.91B, about 41.5x AORT ($1.23B).
- MDLN has been more active in the news (4 items in the past 4 weeks vs 1 for AORT).
- MDLN has more recent analyst coverage (25 ratings vs 8 for AORT).
- Company
- Artivion Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $1.23B
- $50.91B
- 1M return
- -
- +7.57%
- 1Y return
- -
- -4.83%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 1
- 4
- Recent ratings
- 8
- 25
Artivion Inc.
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Latest AORT
- Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
- Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
- SVP, Regulatory and Quality Green Andrew M exercised 44,001 shares at a strike of $13.39 and sold $910,739 worth of shares (44,001 units at $20.70) as part of a pre-agreed trading plan (SEC Form 4)
- Artivion to Participate in the 2026 Truist Securities MedTech Conference
- New insider Green Andrew M claimed ownership of 60,259 shares (SEC Form 3)
- Director Semedo Anthony B. disposed of 6,325 shares and acquired 6,325 shares, decreasing direct ownership by 13% to 40,635 units (SEC Form 4)
- SEC Form SD filed by Artivion Inc.
- Amendment: Director Borgstrom Marna P was granted 7,576 shares, increasing direct ownership by 15% to 56,664 units (SEC Form 4)
- Director Semedo Anthony B. was granted 7,576 shares, increasing direct ownership by 19% to 46,960 units (SEC Form 4)
- Director Salveson Jon W was granted 7,576 shares, increasing direct ownership by 6% to 137,416 units (SEC Form 4)
Latest MDLN
- Medline strengthens California distribution network with new 1 million-square-foot facility in Perris
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)